Khaled Abdelrahman

Dr. Khaled Abdelrahman holds BSc (Pharmaceutical Sciences) and MSc (Pharmacology) from Alexandria University. He received his PhD from the University Calgary where he studied how brain blood vessel function is altered in Type 2 diabetes. He then joined the University of Ottawa to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted to slow the progression of neurodegenerative diseases.

His research was supported by prestigious salary awards from the Canadian institutes for Health Research and Alberta Innovates. He is also a registered pharmacist with over 12 years of clinical expertise in providing patient care.

He is currently an assistant professor in the department of anesthesiology, pharmacology and therapeutics at the University of British Columbia. Khaled’s lab is using in vitro, ex vivo and in vivo tools to study the pathophysiological mechanisms of Alzheimer’s disease and discover novel therapeutic strategies that can reverse pathological changes and slow memory decline in Alzheimer’s disease models.